Related Experiment Video
Updated: Nov 23, 2025
09:31
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
9.5K
Mouse models for mesothelioma drug discovery and development
Kenneth P Seastedt1, Nathanael Pruett2, Chuong D Hoang2
1Department of Surgery, Uniformed Services University of the Health Sciences F. Edward Hébert School of Medicine, Bethesda, Maryland, USA.
Expert Opinion on Drug Discovery
|December 31, 2020
Summary
Mouse models are crucial for mesothelioma drug discovery, but new models are needed to understand inflammation and tumor complexity. Future models, including CRISPR-Cas and humanized mice, will accelerate the development of more effective mesothelioma therapies.
Area of Science:
- Oncology
- Translational Research
Background:
- Mesothelioma is an aggressive cancer of the mesothelial lining.
- Current drug therapies include chemotherapy, targeted therapy, and immunotherapy.
- Existing mouse models have limitations in fully recapitulating mesothelioma's complexity.
Purpose of the Study:
- To review available mouse models for mesothelioma drug discovery.
- To identify knowledge gaps in mesothelioma research.
- To consider future directions for mouse model development.
Main Methods:
- Review of existing literature on mesothelioma mouse models.
- Discussion of advantages and disadvantages of various models.
- Exploration of emerging technologies like CRISPR-Cas and humanized mice.
Main Results:
- Mouse models have been vital for evaluating mesothelioma therapies.
- Gaps exist in understanding inflammation, tumor heterogeneity, carcinogenesis, and the tumor microenvironment.
- Novel mouse models are essential for advancing mesothelioma treatment.
Conclusions:
- CRISPR-Cas gene editing will enhance understanding of mesothelioma mechanisms.
- Precise modeling of inflammation's role in mesothelioma is needed.
- Humanized mouse models with patient-derived xenografts will drive immuno-oncology innovation.
